Mirum Lifts 2026 Sales Guidance to $715-720M After Q3 Revenue Jump to $185.7M
MIRM sits 38% above its 52-week low of $63.232.
Summary
Mirum raised full-year net product sales guidance to $715-720 million after Q3 product sales came in at $185.7 million versus $133.0 million a year earlier. LIVMARLI drove $133.4 million of that, up 45% year-over-year, with Bile Acid Medicines adding $52.3 million, up 28%. The quarter still produced a net loss of $40.8 million, or $0.62 per basic share, as operating expenses climbed to $245.5 million from $130.4 million, including $42.1 million of brelovitug development spend and $13.5 million of acquired IPR&D. This follows the September FDA approval and launch of ATEBRIOZ in FOP and the positive AZURE-1 and EXPAND Phase 3 readouts, which management framed as the base for five potential upcoming approvals and label expansions. Balance sheet shows $500.5 million in cash and investments, and the company retired $20.0 million of its 4.00% convertible notes due 2029, roughly a quarter of the outstanding issue. Next hard data point is AZURE-4 Phase 3 topline in Q4 2026, with full AZURE-1 results due at The Liver Meeting on November 8.
At the time of this announcement, MIRM was trading at $87.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.7B. The 52-week trading range was $63.23 to $130.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.